Bugworks is headquartered in the USA with subsidiaries in India and Australia. They have discovered novel dual target acting microbial agents now in clinical trials. Over the years, They have diversified our expertise in the areas of cancer biology and immunology. Path breaking solutions to large unmet needs in Antimicrobial resistance (AMR) and immuno-oncology. Making highly differentiated assets, affordable and accessible to all of humanity. Bugworks was set up in 2014 and incubated in C-CAMP, Bangalore. The core scientific team comes with a combined experience of over 200 years in Drug Discovery. Bugworks engages with multiple, globally reputed partners to propel its breakthrough broad-spectrum assets.